Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combined-modality therapy in pancreatic cancer: Current status and future directions
Autore:
McGinn, CJ; Zalupski, MM;
Indirizzi:
Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 adiat Oncol, Ann Arbor, MI 48109 USA Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109USA Univ Michigan Ann Arbor MI USA 48109 atol & Oncol, Ann Arbor, MI 48109USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 4, volume: 7, anno: 2001,
pagine: 338 - 348
SICI:
1528-9117(200107/08)7:4<338:CTIPCC>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTRACTED VENOUS INFUSION; COOPERATIVE-ONCOLOGY-GROUP; INTRAOPERATIVE RADIATION-THERAPY; EXTERNAL BEAM IRRADIATION; PHASE-I TRIAL; PREOPERATIVE CHEMORADIATION; LOCALIZED ADENOCARCINOMA; ADJUVANT RADIOTHERAPY; CONCURRENT RADIATION; CURATIVE RESECTION;
Keywords:
combined modality therapy; pancreatic neoplasms; clinical trials;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: McGinn, CJ Univ Michigan, Dept Radiat Oncol, 1500 E Med Ctr Dr, Ann Arbor,MI 48109 USA Univ Michigan 1500 E Med Ctr Dr Ann Arbor MI USA 48109 8109 USA
Citazione:
C.J. McGinn e M.M. Zalupski, "Combined-modality therapy in pancreatic cancer: Current status and future directions", CANCER J, 7(4), 2001, pp. 338-348

Abstract

The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group (GITSG) trials, which have included 5-fluorouracil (5-FU). Unfortunately, the majority of patients continue to succumb to the disease process. Recently, there has been a resurgence in clinical trials investigating alternative combined modality treatmentstrategies for patients with pancreatic cancer. In this review, we will summarize both the mature and more recent data pertaining to combined modality therapy for patients with unresectable or resected pancreatic cancer. Strategies utilizing concurrent gemcitabine, alternative radiation therapy techniques, and/or altered sequencing of therapies will be highlighted. Such modifications to the approach in use since the 1980s will need to be fully considered as clinical trials utilizing chemoradiotherapy regimens and new systemic agents or novel targeted therapies are designed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 08:28:29